Factors Associated with Promoted Proliferation of Osteosarcoma by Peptidylarginine Deiminase 4

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Osteosarcoma is the most common primary bone cancer, but its pathogenesis is not fully understood.
• Peptidylarginine deiminase 4 (PADI4), an enzyme involved in deimination, plays a role in various human cancers.
• The specific role of PADI4 in osteosarcoma tumorigenesis requires further investigation.

Purpose of the Study:

• To investigate the effect of PADI4 on osteosarcoma cell proliferation.
• To elucidate the underlying molecular mechanisms by which PADI4 influences osteosarcoma.
• To assess the clinical relevance of PADI4 expression in osteosarcoma tissues and its impact on tumor growth.

Main Methods:

• Cell proliferation was assessed using the CCK8 assay and colony formation assay.
• Signaling pathways, including Wnt/β-catenin and MEK/ERK, were analyzed.
• PADI4 expression was examined in human osteosarcoma tissues.
• In vivo experiments were conducted using nude mice to evaluate tumor growth.

Main Results:

• Ectopic expression of PADI4 enhanced the proliferation and colony formation capacity of osteosarcoma cells (U2OS and Saos-2).
• PADI4 was found to stimulate both the Wnt/β-catenin and MEK/ERK signaling pathways.
• Differential expression of PADI4 correlated with osteosarcoma tumorigenesis.
• In vivo studies confirmed that PADI4 affects tumor growth in osteosarcoma models.

Conclusions:

• PADI4 significantly upregulates osteosarcoma proliferation, primarily through the activation of Wnt/β-catenin and MEK/ERK signaling.
• This study provides novel insights into the regulatory mechanisms of osteosarcoma proliferation.
• PADI4 emerges as a promising biomarker for osteosarcoma diagnosis and a potential therapeutic target for treatment.